PTO/SB/96 (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: Monogram Biosciences, Inc.
Application No./Patent No.: 10/612,600 / 7,553,618 Filed/Issue Date: 07/01/2003 / 06/30/2009
Titled: METHOD FOR DETERMINING HUMAN IMMUODEFICIENCY VIRUS TYPE 1 (HIV-1) HYPERSUSCEPTIBILITY TO THE PROTEASE INHIBITOR AMPRENAVIR
Monogram Biosciences, Inc, acorporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
states that it is:
1. X the assignee of the entire right, title, and interest in;
an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
the patent application/patent identified above, by virtue of either:
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a
copy therefore is attached. OR
B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From: Inventors To: Virologic, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 014882, Frame 0962, or for which a copy thereof is attached.
- A II Marrows Cultaridians II C
2.170111
The document was recorded in the United States Patent and Trademark Office at Reel 022825 , Frame 0988 , or for which a copy thereof is attached.
3. From: Apollo Merger Subsidiary, LLC To: Virologic, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 022827 Frame 0166 or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet(s).
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
Signature
Charles W. Calkins (Reg. No. 31,814) Attorney for Applicant
Printed or Typed Name Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

STATEMENT UNDER 37 CFR 3.73(b)
Applicant/Patent Owner: Monogram Biosciences, Inc.
Application No./Patent No.: 10/612,600 / 7,553,618 Filed/Issue Date: 07/01/2003 / 06/30/2009
Titled: METHOD FOR DETERMINING HUMAN IMMUODEFICIENCY VIRUS TYPE 1 (HIV-1) HYPERSUSCEPTIBILITY TO THE PROTEASE INHIBITOR AMPRENAVIR
Monogram Biosciences, Inc. , a corporation
(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
states that it is:
1. X the assignee of the entire right, title, and interest in;
an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is%); or
3. the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
the patent application/patent identified above, by virtue of either:
An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or for which a
copy therefore is attached. OR
B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
1. From: Virologic, Inc. To: Monogram Biosciences, Inc.
The document was recorded in the United States Patent and Trademark Office at Reel 022827 , Frame 0394 , or for which a copy thereof is attached.
2. From: Monogram Biosciences, Inc. To: Pfizer, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 017681 , Frame 0183 , or for which a copy thereof is attached.
3. From: Pfizer, Inc. To: Monogram Biosciences, Inc.
The document was recorded in the United States Patent and Trademark Office at
Reel 023364 , Frame 0305 , or for which a copy thereof is attached.
Additional documents in the chain of title are listed on a supplemental sheet(s).
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Divisio accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]
The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
#3 0/10
Signature
Charles W. Calkins (Reg. No. 31,814) Attorney for Applicant
Printed or Typed Name Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.